IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Shares Bought by Voloridge Investment Management LLC

Voloridge Investment Management LLC raised its holdings in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 50.7% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 286,759 shares of the company's stock after purchasing an additional 96,466 shares during the period. Voloridge Investment Management LLC owned 0.33% of IDEAYA Biosciences worth $7,370,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also made changes to their positions in the company. Barclays PLC raised its stake in IDEAYA Biosciences by 188.8% in the third quarter. Barclays PLC now owns 181,170 shares of the company's stock valued at $5,739,000 after buying an additional 118,438 shares during the period. SG Americas Securities LLC raised its position in shares of IDEAYA Biosciences by 444.2% in the 4th quarter. SG Americas Securities LLC now owns 18,486 shares of the company's stock worth $475,000 after acquiring an additional 15,089 shares in the last quarter. KBC Group NV raised its position in shares of IDEAYA Biosciences by 84.6% in the 4th quarter. KBC Group NV now owns 4,197 shares of the company's stock worth $108,000 after acquiring an additional 1,923 shares in the last quarter. R Squared Ltd bought a new stake in IDEAYA Biosciences in the 4th quarter valued at about $35,000. Finally, China Universal Asset Management Co. Ltd. boosted its stake in IDEAYA Biosciences by 12.8% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 18,327 shares of the company's stock valued at $471,000 after purchasing an additional 2,078 shares during the last quarter. 98.29% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on the company. JPMorgan Chase & Co. boosted their target price on IDEAYA Biosciences from $63.00 to $66.00 and gave the stock an "overweight" rating in a research note on Thursday, May 22nd. Stephens reiterated an "overweight" rating and set a $50.00 price target on shares of IDEAYA Biosciences in a report on Friday, February 14th. Two equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $54.27.

IDEAYA Biosciences Stock Down 0.0%

IDYA stock traded down $0.01 during mid-day trading on Friday, hitting $20.04. 989,893 shares of the company were exchanged, compared to its average volume of 1,008,415. The business has a fifty day simple moving average of $17.74 and a 200-day simple moving average of $21.60. IDEAYA Biosciences, Inc. has a 12-month low of $13.45 and a 12-month high of $44.42. The firm has a market capitalization of $1.76 billion, a P/E ratio of -6.09 and a beta of 0.26.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The company reported ($0.82) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.07). During the same period in the prior year, the firm posted ($0.53) EPS. Research analysts predict that IDEAYA Biosciences, Inc. will post -3.07 EPS for the current year.

About IDEAYA Biosciences

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.